Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard


Aurora Cannabis
TSX: ACB
NYSE: ACB
Sector: Healthcare
Industry: Legal Cannabis
Country: Canada
Employees: >1400 as of 9/2018
Established: 2013
CEO: Terry Booth

Summary

Fiscal Year-End: June 30
Licensed Facilities: 11
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: 67,484 at 9/30/18
Headquarters: Vancouver, BC

Financials (09/30/18)

Cash on hand: $147.8mm
Fixed Investment: $449.9mm
Shareholders’ Equity: $4.40 billion
Revenues – Last Quarter: $29.7mm
Adj. Gross Margin: 67.8%
EPS : $0.12

Capital Structure (11/09/18)

Last Equity Fin: $230mm Convertible Notes at $13.05
Basic Shares: 965.1mm
Warrants: 22.6mm
Options: 42.2mm
Diluted Shares: 1049.6mm

Company Brief

Aurora is one of the world’s largest and fastest growing cannabis companies. Following the acquisition of MedReleaf, the company has more than 1,500 employees, 11 facilities, and a funded annual production capacity of more than 500,000 kilograms per year. The Company is vertically integrated and horizontally diversified across every key segment of the cannabis value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company’s purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. Aurora’s growing constellation of subsidiaries and strategic partnerships provide differentiation in terms of geographic reach, production, technology, product offering, and execution.

With a growing number of countries adopting medical cannabis legislation, the Company has embarked on an aggressive international expansion strategy that currently sees Aurora with operations and/or sales in 22 countries across five continents.

Featured Video

James West interviews CCO Cam Battley about the company’s Q1 2019 financial results, which saw Aurora’s pro-forma revenue increase 333 percent to $35.8 million. Battley says that Aurora’s earnings are “by the far the most powerful revenue quarter that any cannabis company has delivered.”


Differentiators

Canadian Operations

  • Multiple state-of-the-art facilities in operation or under construction in four provinces
  • Recent acquisitions of CanniMed and MedReleaf leave the company with nine facilities in Canada
  • Ownership of CanvasRx, the largest operator of cannabis clinics in Canada with 35 clinics open
  • Strong product portfolio with Aurora, CanniMed, and MedReleaf brands and wellness brands including San Rafael ’71, Woodstock, and AltaVie
  • Same-day delivery in Alberta and innovative mobile ordering app
  • Supply agreements with 12 provinces and territories
  • Agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart to distribute and sell medical cannabis
  • 40 clinical studies completed or ongoing
  • Large investment portfolio including TGOD, Radient Technologies, Hempco, Alcanna (formerly Liquor Stores N.A.), and more

Global Operations

  • Active in five continents and 22 countries
  • 22.9% ownership of Australia’s Cann Group (ASX: CAN)
  • 51% ownership of Aurora Nordic in Denmark
  • Ownership of German distribution company Pedanios
  • Wholly owned subsidiary ICC Labs gives the company a platform in Latin America
  • Acquired European hemp company Agropro and sister company Borela
  •  Supply agreements in Italy, South Africa, Luxembourg, and Mexico
  • Import permit from the Polish Ministry of Health
  • Approved for the first cannabis cultivation facility in Malta
  • Structured investment in spin-off Australis Capital, which positions the company to benefit from eventual U.S. legalization

Institutional Analyst Coverage

MATT BOTTOMLEY
Canaccord Genuity

MARTIN LANDRY
GMP Securities

GRAEME KREINDLER
Eight Capital

JASON ZANDBERG
PI FINANCIAL

TAMY CHEN
BMO Nesbitt Burns

GREG MCLEISH, CFA
Mackie Research


Curated Stories & News


Visit Aurora Cannabis
at www.auroramj.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.